Navigation Links
Former Executive at Genzyme Corp. and Osiris Therapeutics, Inc. to Head Business Advisory Board at Rx for Africa, Inc.
Date:4/13/2009

NEW YORK, April 13 /PRNewswire-FirstCall/ -- A top biotech executive, William Pursley, has agreed to become Chairman of Rx for Africa, Inc.'s (Pink Sheets: RXAF) newly created Business Advisory Board. For 25 years Mr. Pursley has held major executive positions in the biotech industry. In 1985 he joined Genentech, Inc., and was on the marketing team that launched Human Growth Hormone (HGH), one of biotech's first products. It was a huge success. In 1985 Pursley joined Genzyme Corp as VP of Marketing and spearheaded the launch of Ceradase, an Orphan Drug for the treatment of Gaucher's Disease. Only 3,000 people in the US suffer from Gaucher's. Hopes were that the drug would reach $40 million in sales by the third year on the market. It did $120 million in year three. Ceradase has gone on to be Genzyme's biggest seller. It's sales currently exceed $600 million. Genzyme's market cap exceeds $18 billion. Mr. Pursley subsequently became CEO of Osiris Therapeutics, Inc., a leading mesenchymal stem cell company, which recently announced a major corporate alliance with Genzyme.

In 1999, Mr. Pursley joined Transkaryotic Therapeutics as Senior VP of Operations, supervising the European launch of the company's first product, Replagal, an orphan drug for Fabry's disease. The drug took 75% market share in Europe. In 2005, Transkaryotic was sold to Shire Pharmaceuticals for $1.6 billion. He has also achieved great success with reimbursement programs for the drugs he has marketed. "With Ceradase, we were successful in getting insurance companies to reimburse patients up to $350,000 a year for their treatment. Today, in Africa, there are multi-billion dollar funds such as PEPFAR and The Global Fund set up to reimburse companies who distribute drugs for disease such as HIV and malaria. I believe I can help Rx access these funds."

Pursley, who has experience marketing drugs in Africa, sees huge growth ahead for the continent. "Once the global r
'/>"/>

SOURCE Rx for Africa, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. 4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote Recovery Happens! Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento
2. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, to Address National Drug Crisis, Keynote Grand Opening of New Allenwood, PA National Model Detox Center
3. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
4. Former State Representative Terry Parke Joins Secure Services Corp.
5. Benjamin England, Former FDA Regulatory Counsel, to Testify on FDA Import Strategic Plan Before House Appropriations Subcommittee
6. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, & Countrys Top Drug Treatment CEO Barry Karlin to Keynote Palm Beach, FL National Moment Of Change Intervention Conference:
7. Former Ronco President Tim Dupler Signs International Direct Sales and Marketing Contract with Natural Nutrition
8. Former HHS Secretary Dr. Louis Sullivan, Lt. Gov. Cagle Address Need to Improve Quality of Patient Care
9. Former Pfizer Patent Attorneys Join Brinks Hofer Gilson & Lione
10. Nobel Honors 3 Former March of Dimes Prize Recipients
11. Over one-third of former American football players had sexual relations with men, study says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... PA (PRWEB) August 23, 2014 "I ... when they gave a urine sample," said an inventor ... entire process easier and mess-free, I came up with ... to allow urine samples to be collected from women ... peace of mind to patients and staff. The invention ...
(Date:8/23/2014)... The report “Polycarbonate Resin Market ... to 2018” defines and segments the global polycarbonate ... global revenue and consumption. It also identifies driving ... market with analysis of trends, opportunities, burning issues, ... and revenues are forecasted on the basis of ...
(Date:8/23/2014)... August 23, 2014 Peripheral intervention surgeries ... remove plaques, etc, thereby addressing the root cause of ... of blood to the other part of the arteries ... blood. These procedures require the use of a catheter, ... and polymers), these catheters are inserted through a thin ...
(Date:8/23/2014)... Pittsburgh, PA (PRWEB) August 23, 2014 Having ... inventor and dental hygienist from Arlington, Texas, saw a need ... toothbrush and toothpaste. "That’s when I came up with the ... easy-to-use No-Brush provides an effective way for a user to ... the need to carry multiple items. It also helps avoid ...
(Date:8/23/2014)... Raleigh, NC (PRWEB) August 23, 2014 A ... IMRT for mesothelioma last longer when preceded by surgery and ... an article on the new study. Click here to ... Cancer Center studied the cases of mesothelioma patients ... technique for conforming radiotherapy dose to the shape of a ...
Breaking Medicine News(10 mins):Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 4Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2
... Following is a,media statement attributable to Betsy ... Hospital Association:, "NJHA applauds the state upon ... This is a valuable document for New Jersey,s,hospitals ... a wealth of information on which hospitals can,focus ...
... Gaps in ... Breast Cancer Care, Survival, COLUMBUS, Ohio, Jan. 17 ... the Cure will host two events to,launch Ohio,s participation in the ... cancer care that cause some women to die,of the disease more ...
... Immunosyn,Corporation (OTC Bulletin Board: IMYN) announced today ... Concept Trial" for the biopharmaceutical SF-1019 has,been successfully ... The Board of Immunosyn was advised as ... "Proof of Concept Trial" by Argyll Biotechnologies, LLC ...
... of ongoing clinical trials, expert says , , THURSDAY, Jan. 17 ... or prevent Alzheimer,s disease, a new study finds no evidence ... suggested this possibility, whether the same benefit translates to humans ... find a relation between statin use and the risk of ...
... January 18 edition (Volume 28, Issue 1) of the journal ... is known as a nonsense mutation of the Coronin-1A gene ... mutation causes the gene to produce proteins that no longer ... cytoskeleton, a network of protein fibers or filaments in the ...
... from injuries, disease , THURSDAY, Jan. 17 (HealthDay ... creating the brain,s thinking center, in a finding that ... neurodegenerative diseases. , The gene, called Lhx2, tells stem ... cortex, which controls functions such as language, decision-making and ...
Cached Medicine News:Health News:Susan G. Komen for the Cure, U.S. Congressman Pat Tiberi, Ohio Senator Tom Niehaus, and OhioHealth Riverside Breast Health Center Call for Action on Breast Cancer 2Health News:Immunosyn Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019 2Health News:Immunosyn Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019 3Health News:Latest Study Says Statins Don't Slow Alzheimer's 2Health News:Scripps research scientists find new genetic mutation that halts the development of lupus 2Health News:Scripps research scientists find new genetic mutation that halts the development of lupus 3
(Date:8/22/2014)... 2014  Landauer, Inc. (NYSE: LDR ), ... and monitoring, outsourced medical physics services and high quality ... Saxelby , its President and Chief Executive Officer, will ... and as a member of the Board of Directors, ... replaced on an interim basis by Michael T. ...
(Date:8/22/2014)... Aug. 22, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) ... of units of common stock and warrants at a ... $20 million, prior to deducting underwriting discounts and commissions ... and warrants are immediately separable and will be issued ... begin trading on The NASDAQ Stock Market under the ...
(Date:8/21/2014)... Hermann Health System and The University of Texas ... to provide a new level of specialized breast screening at ... Houston area. Starting in ... professional breast radiology services for five of Memorial Hermann,s 10 ... Woodlands , Northeast, Southwest and Sugar Land ...
Breaking Medicine Technology:Landauer, Inc. Announces Executive Management Change 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4
... Roper Industries, Inc. (NYSE: ROP ) ... (CUSIP No. 776696AA4) (the "Notes") will accrue contingent interest for ... at an annual rate of 0.25% of the average market ... January 12, 2011. Contingent cash interest, which the Company has ...
... 18, 2011 Soligenix, Inc. (Soligenix or the ... a late-stage biopharmaceutical company, announced today promising preliminary ... beclomathasone dipropionate or BDP) in a canine gastrointestinal ... that dogs treated with SGX202 demonstrated statistically significant (p=0.04) ...
Cached Medicine Technology:Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 2Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 3Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 4Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 5
... HPLC system designed to provide fast and ... aid in the comprehensive identification and quantitation ... glycemic control., ,The A1c assay combines the ... accuracy of boronate affinity columns. The result ...
... fastest blood gas analyzers for ... on the market. Equally suitable ... testing. The Roche COMPACT ... reliable assessment of acid-base status ...
... sets the standard for testing blood ... at your patient's side - the ... self contained system can easily be ... ICU, or wherever you need it ...
Flatbed Agitator....
Medicine Products: